Key result
SSRI exposure shows no significant link to lower overall MI risk except during longer-term use.
Why the study?
Does selective serotonin re-uptake inhibitor (SSRI) exposure reduce the risk of myocardial infarction in patients with depression?
Case-Control (n=3,465)
Does selective serotonin re-uptake inhibitor (SSRI) exposure reduce the risk of myocardial infarction in patients with depression?
Odds Ratio: 0.77 (95% CI 0.57–1.03)
Longer-term use of SSRIs in patients with depression may be associated with a reduced risk of myocardial infarction, potentially through mechanisms beyond acute anti-platelet effects.
SSRI use in depression may lower MI risk; leaves open causal confirmation in RCTs.
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Depression is associated with an increased risk of cardiovascular disease. Some studies, but not all, have identified an association between use of selective serotonin re‐uptake inhibitors (SSRIs) and reduced risk of myocardial infarction (MI). There may be a difference among SSRIs based on their affinity for the serotonin receptor. WHAT THIS STUDY ADDS • Current use of SSRIs by patients with depression may be associated with a reduced risk of MI. However, the risk seemed to be reduced only with longer term use of SSRIs. In addition, we did not observe a relationship between the affinity of SSRIs for the serotonin transporter and risk of MI. AIM To evaluate whether selective serotonin re‐uptake inhibitor (SSRI) exposure influences the risk of myocardial infarction (MI) in patients with depression. METHODS This study included 693 patients with MI (cases) and 2772 controls. Conditional logistic regression was used to calculate the odds ratio (OR). RESULTS SSRI exposure may be associated with a reduced MI risk (OR = 0.77, 95% CI 0.57, 1.03). However, reduced risk was only observed with longer term use (OR = 0.73, 95% CI 0.53, 1.00) and not with shorter term use (OR = 1.15, 95% CI: 0.65, 2.05). CONCLUSIONS Only longer term use of SSRIs was associated with reduced MI risk, suggesting that other mechanisms, besides an acute anti‐platelet effect, may reduce MI risk.
No takes yet. Share an insight, caveat, or question.
Kimmel et al. (2011) conducted a case-control in Depression (n=3,465). Selective serotonin re-uptake inhibitors (SSRIs) vs. Non-exposure / Controls was evaluated on Myocardial infarction (OR 0.77, 95% CI 0.57-1.03). SSRI exposure in patients with depression was associated with a non-significant reduction in overall MI risk (OR 0.77; 95% CI 0.57-1.03), with reduced risk observed only during longer-term use.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: